Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer : a retrospective cohort study

Show full item record



Permalink

http://hdl.handle.net/10138/234329

Citation

Järvinen , T , Ilonen , I , Kauppi , J , Salo , J & Räsänen , J 2018 , ' Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer : a retrospective cohort study ' , World Journal of Surgical Oncology , vol. 16 , 27 . https://doi.org/10.1186/s12957-018-1327-4

Title: Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer : a retrospective cohort study
Author: Järvinen, Tommi; Ilonen, Ilkka; Kauppi, Juha; Salo, Jarmo; Räsänen, Jari
Contributor: University of Helsinki, Clinicum
University of Helsinki, Department of Surgery
University of Helsinki, III kirurgian klinikka
University of Helsinki, III kirurgian klinikka
University of Helsinki, III kirurgian klinikka
Date: 2018-02-12
Language: eng
Number of pages: 9
Belongs to series: World Journal of Surgical Oncology
ISSN: 1477-7819
URI: http://hdl.handle.net/10138/234329
Abstract: Background: Nutritional deficits, cachexia, and sarcopenia are extremely common in esophageal cancer. The aim of this article was to assess the effect of loss of skeletal muscle mass during neoadjuvant treatment on the prognosis of esophageal cancer patients. Methods: Esophageal cancer patients (N = 115) undergoing neoadjuvant therapy and surgery between 2010 and 2014 were identified from our surgery database and retrospectively analyzed. Computed tomography imaging of the total cross-sectional muscle tissue measured at the third lumbar level defined the skeletal muscle index, which defined sarcopenia (SMI <52.4 cm2/m2 for men and <38.5 cm2/m2 for women). Images were collected before and after neoadjuvant treatments. Results: Sarcopenia in preoperative imaging was prevalent in 92 patients (80%). Median overall survival was 900 days (interquartile range 334-1447) with no difference between sarcopenic (median = 900) and non-sarcopenic (median = 914) groups (p = 0.872). Complication rates did not differ (26.1% vs 32.6%, p = 0.725). A 2.98% decrease in skeletal muscle index during neoadjuvant treatment correlated with poor 2-year survival (log-rank p = 0.04). Conclusion: Loss of skeletal muscle tissue during neoadjuvant treatment correlates with worse overall survival.
Subject: Esophageal neoplasms
Thoracic surgery
Sarcopenia
Body composition
Malnutrition
ESOPHAGOGASTRIC JUNCTION
BODY-COMPOSITION
SARCOPENIA
CHEMOTHERAPY
SURVIVAL
RESECTION
TERM
SURGERY
IMPACT
COMPLICATIONS
3122 Cancers
3126 Surgery, anesthesiology, intensive care, radiology
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
s12957_018_1327_4.pdf 1.785Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record